Gene expression profiling of EGFR positive cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 3, 2012
Grant Date -
Oct 6, 2011
app pub date -
Jun 1, 2011
filing date -
Nov 15, 2002
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully